TransCode Therapeutics Receives Notice of Award from National Institutes of Health NIH for Third Year of Grant to Support Clinical Evaluation of TTXMC138

BOSTON, April 05, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded the third year of a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support the clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate for the treatment of advanced solid tumors. The award totals nearly $871,000. “We are honored that the NIH recognizes and continues to support our mission to overcome the obstacles of RNA delivery in oncology,” said Michael Dudley, President and Chief Executive Officer…